BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,296,244 | +86.3% | 49,156 | +17.1% | 0.16% | +98.7% |
Q1 2023 | $695,896 | -80.7% | 41,972 | -80.6% | 0.08% | -79.8% |
Q4 2021 | $3,607,000 | +114.1% | 216,254 | +501.4% | 0.39% | +203.1% |
Q3 2021 | $1,685,000 | +7.2% | 35,956 | +39.5% | 0.13% | -7.9% |
Q2 2021 | $1,572,000 | – | 25,782 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |